Related Experiment Video
Updated: Jun 8, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Infliximab monotherapy for ulcerative colitis-related severe enteritis following colectomy in a paediatric patient
Mohana Sathiaseelan1, Kei Yu Chiu2, Alicia Lim2
1Dept of Gastroenterology and Hepatology, Perth Children's Hospital, Nedlands, Western Australia, Australia mo_mona23@yahoo.com.
Insights
Ulcerative colitis-related severe enteritis (UCRSE) is a rare complication after colectomy, primarily seen in adults. This case highlights successful treatment with infliximab (IFX) in a young patient.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease
- Surgical Complications
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Colectomy is a treatment option for severe, refractory UC.
- Ulcerative colitis-related severe enteritis (UCRSE) is a rare post-colectomy complication.
Observation:
- A pediatric patient with medically refractory UC underwent colectomy.
- Postoperatively, the patient developed fever, severe abdominal pain, and high stoma output.
- Endoscopy revealed extensive enteritis with histology consistent with UC.
Findings:
- Infliximab (IFX) therapy was initiated for the severe enteritis.
- The patient showed significant clinical improvement with IFX.
- This represents the youngest reported case of UCRSE.
Implications:
- UCRSE should be considered in pediatric patients presenting with unexplained post-colectomy symptoms.
- Infliximab monotherapy is a viable and effective treatment for UCRSE in children.
- Early diagnosis and treatment can lead to favorable outcomes in UCRSE.
Abstract:
We report the rare entity of ulcerative colitis-related severe enteritis (UCRSE) following colectomy in a child. This entity has been described primarily in adults and is characterised by diffuse enteritis with histology identical to ulcerative colitis (UC). The mainstay treatment is steroids and in recent years anti-tumour necrosis factor agents.A boy in early adolescence required urgent colectomy for medically refractory severe acute colitis. Colectomy specimen histology confirmed UC. Postoperatively, he developed fevers, severe abdominal pain and excessive stoma output (5 L/day). Endoscopy revealed severe extensive enteritis, histologically resembling UC. Infliximab (IFX) was commenced with significant improvement. He remains asymptomatic 28 months post-colectomy on maintenance IFX monotherapy. To our knowledge, this is the youngest patient with this complication.This case illustrates the need to consider UCRSE in a child with otherwise unexplained fever, severe abdominal pain and high stoma output post colectomy. IFX monotherapy is a successful treatment option.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: